Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
AI-powered ECG screening boosts outcomes | Predicting post-TAVR mortality
Friday, November 4, 2022
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Today's News and Trends

AI-powered ECG screening boosts patient outcomes—when clinicians give it a chance

New research out of Mayo Clinic found that clinicians who listened to AI-based treatment recommendations were more successful at identifying patients with low ejection fraction. 

READ MORE >
Tablet projecting metaphorical medical hologram
Share on Twitter Share on Facebook Share on Linkedin

AI-powered ECG screening boosts patient outcomes—when clinicians give it a chance

Share on Twitter Share on Facebook Share on Linkedin
Tablet projecting metaphorical medical hologram
New research out of Mayo Clinic found that clinicians who listened to AI-based treatment recommendations were more successful at identifying patients with low ejection fraction. 
READ MORE >

Predictors of 1-year mortality after TAVR are significantly different among men and women

Atrial fibrillation and peripheral artery disease, for example, are both predictors of mortality among women, but not men. 

READ MORE >
A transcatheter aortic valve replacement (TAVR) procedure being performed at Intermountain Healthcare. Image from Intermountain Healthcare. Sex differences in TAVR one-year mortality.
Share on Twitter Share on Facebook Share on Linkedin

Predictors of 1-year mortality after TAVR are significantly different among men and women

Share on Twitter Share on Facebook Share on Linkedin
A transcatheter aortic valve replacement (TAVR) procedure being performed at Intermountain Healthcare. Image from Intermountain Healthcare. Sex differences in TAVR one-year mortality.
Atrial fibrillation and peripheral artery disease, for example, are both predictors of mortality among women, but not men. 
READ MORE >

Featured Articles

Cardiologists, electrophysiologists ‘disappointed’ in final 2023 Medicare Physician Fee Schedule

The American College of Cardiology and Heart Rhythm Society issued a joint statement soon after CMS published its final rule for the 2023 Medicare Physician Fee Schedule. The groups warned that the final rule could threaten patient access to high-quality care. 

READ MORE >
The American College of Cardiology and Heart Rhythm Society issued a joint statement soon after CMS published its final rule for the 2023 Medicare Physician Fee Schedule. The groups warned that the final rule could threaten patient access to high-quality care. Medicare cuts may harm patient care.
Share on Twitter Share on Facebook Share on Linkedin

Cardiologists, electrophysiologists ‘disappointed’ in final 2023 Medicare Physician Fee Schedule

Share on Twitter Share on Facebook Share on Linkedin
The American College of Cardiology and Heart Rhythm Society issued a joint statement soon after CMS published its final rule for the 2023 Medicare Physician Fee Schedule. The groups warned that the final rule could threaten patient access to high-quality care. Medicare cuts may harm patient care.
The American College of Cardiology and Heart Rhythm Society issued a joint statement soon after CMS published its final rule for the 2023 Medicare Physician Fee Schedule. The groups warned that the final rule could threaten patient access to high-quality care. 
READ MORE >

VIDEO: SYMPLICITY HTN-3 and the future of renal denervation

Deepak Bhatt, MD, MPH, details long-term outcomes from the SYMPLICITY HTN-3 trial, which show a lasting impact on patients with uncontrolled hypertension. 

READ MORE >
Deepak Bhatt, MD, discusses the long-term, positive SYMPLICITY HTN-3 trial results presented at TCT 2022, and the future of renal denervation therapy to treat hypertension. #TCT
Share on Twitter Share on Facebook Share on Linkedin

VIDEO: SYMPLICITY HTN-3 and the future of renal denervation

Share on Twitter Share on Facebook Share on Linkedin
Deepak Bhatt, MD, discusses the long-term, positive SYMPLICITY HTN-3 trial results presented at TCT 2022, and the future of renal denervation therapy to treat hypertension. #TCT
Deepak Bhatt, MD, MPH, details long-term outcomes from the SYMPLICITY HTN-3 trial, which show a lasting impact on patients with uncontrolled hypertension. 
READ MORE >

Late-breaking study examines IVL’s safety and effectiveness among real-life PAD patients

The new study, based on data from nearly 1,400 PAD patients who were treated with Shockwave Medical's IVL technology, was presented at VIVA22 in Las Vegas. 

READ MORE >
Intravascular lithotripsy (IVL) therapy to break up calcified coronary lesions will now be reimbursed at a higher rate under new in-hospital codes the went into effect Oct. 1. Illustration of the Shockwave lithoplasty procedure using sonic waves to bust calcium without trauma.
Share on Twitter Share on Facebook Share on Linkedin

Late-breaking study examines IVL’s safety and effectiveness among real-life PAD patients

Share on Twitter Share on Facebook Share on Linkedin
Intravascular lithotripsy (IVL) therapy to break up calcified coronary lesions will now be reimbursed at a higher rate under new in-hospital codes the went into effect Oct. 1. Illustration of the Shockwave lithoplasty procedure using sonic waves to bust calcium without trauma.
The new study, based on data from nearly 1,400 PAD patients who were treated with Shockwave Medical's IVL technology, was presented at VIVA22 in Las Vegas. 
READ MORE >

In Case You Missed It

VIDEO: The role of AI in cardiac imaging

Ed Nicol, MD, president-elect of the Society of Cardiovascular Computed Tomography, provided us with an exclusive look at how AI is expected to change cardiac imaging.

READ MORE >
AI-generated coronary tree from a patient's CT scan showing a color code of areas of interest for plaque burden from the Cleerly software shown at SCCT 2022.
Share on Twitter Share on Facebook Share on Linkedin

VIDEO: The role of AI in cardiac imaging

Share on Twitter Share on Facebook Share on Linkedin
AI-generated coronary tree from a patient's CT scan showing a color code of areas of interest for plaque burden from the Cleerly software shown at SCCT 2022.
Ed Nicol, MD, president-elect of the Society of Cardiovascular Computed Tomography, provided us with an exclusive look at how AI is expected to change cardiac imaging.
READ MORE >

Cordis to acquire MedAlliance, known for its drug-eluting balloons, in deal that could surpass $1B

The acquisition includes an initial investment of $35 million and an upfront closing payment of $200 million. By 2029, if the companies reach all targeted regulatory and commercial milestones, the acquisition could cost Cordis up to $1.135 billion in all.

READ MORE >
Cordis acquires MedAlliance, known for its drug-eluting balloon technology, in deal that could surpass $1B
Share on Twitter Share on Facebook Share on Linkedin

Cordis to acquire MedAlliance, known for its drug-eluting balloons, in deal that could surpass $1B

Share on Twitter Share on Facebook Share on Linkedin
Cordis acquires MedAlliance, known for its drug-eluting balloon technology, in deal that could surpass $1B
The acquisition includes an initial investment of $35 million and an upfront closing payment of $200 million. By 2029, if the companies reach all targeted regulatory and commercial milestones, the acquisition could cost Cordis up to $1.135 billion in all.
READ MORE >

In Other News

Too much medical imaging, too little time to fix what’s broken?

A leading U.K. radiologist tells what he saw as this challenging scenario snowballed into being and what he believes must be done to make matters more manageable.

READ MORE >
snowball.jpg
Share on Twitter Share on Facebook Share on Linkedin

Too much medical imaging, too little time to fix what’s broken?

Share on Twitter Share on Facebook Share on Linkedin
snowball.jpg
A leading U.K. radiologist tells what he saw as this challenging scenario snowballed into being and what he believes must be done to make matters more manageable.
READ MORE >

AI identifies breast lesion subtypes, could prevent unnecessary biopsies

In a new paper in Radiology, experts explain how the use of artificial intelligence to identify lesion subtypes could benefit both clinics and patients. 

READ MORE >
rsnavirtualbiop.jpeg
Share on Twitter Share on Facebook Share on Linkedin

AI identifies breast lesion subtypes, could prevent unnecessary biopsies

Share on Twitter Share on Facebook Share on Linkedin
rsnavirtualbiop.jpeg
In a new paper in Radiology, experts explain how the use of artificial intelligence to identify lesion subtypes could benefit both clinics and patients. 
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

AI is gaining ground, but clinicians run the show | Siemens Healthineers doubles down | Electrophysiologist compensation
News Alert: FDA shares warning about heart valve tech after patient death
Cardiologist pay & productivity are up | FDA clears PE thrombectomy devices | Cardiology tech in spotlight | Gore's new approval
Cardiology salaries on the rise | The climbing costs of care | M&A trends | Siemens Healthineers, J&J make big business moves
Major MRI trends | Blood thinner recalled | When to perform PCI before TAVR | How to build a CCTA program | Steroids & the heart
CMS boosts coverage for heart failure tech | FDA approves CardioMEMS updates | LVADs linked to strokes, other risks
M&A activity in cardiology: Exploring key trends | Cardiac PET vs. SPECT | Doctors support Medicare covering TAVR for AR
Newsletter archive
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
  • Press Releases
  • Submit Press Release
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
Design by Adaptive Theme